Alimera Sciences Inc  

(Public, NASDAQ:ALIM)   Watch this stock  
Find more results for ALIM
4.77
-0.11 (-2.25%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.71 - 4.92
52 week 1.76 - 8.44
Open 4.92
Vol / Avg. 103,288.00/465,815.00
Mkt cap 209.71M
P/E     -
Div/yield     -
EPS -1.05
Shares 42.97M
Beta 1.38
Inst. own 91%
Nov 10, 2014
Q3 2014 Alimera Sciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 1, 2014
Alimera Sciences Inc Conference Call to discuss the Details On FDA Approval Of ILUVIEN
Aug 7, 2014
Q2 2014 Alimera Sciences Inc Earnings Call
Aug 7, 2014
Q2 2014 Alimera Sciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 50.96% -2469.50%
Operating margin -292.15% -1845.99%
EBITD margin - -1830.45%
Return on average assets 9.32% -128.16%
Return on average equity - -
Employees 31 -
CDP Score - -

Address

Suite 290, 6120 Windward Parkway
ALPHARETTA, GA 30005
United States - Map
+1-678-5275740 (Phone)
+1-678-9905744 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alimera Sciences, Inc.is a biopharmaceutical company that develops and commercializes prescription ophthalmic pharmaceuticals. The Company advanced product candidate, ILUVIEN, is a tiny, cylindrical polyimide tube that contains 190 g of fluocinolone acetonide (FAc), a corticosteroid with a history of treating ocular diseases. ILUVIEN is in development for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. The Company is based in Alpharetta, Georgia, United States.

Officers and directors

Philip R. Tracy J.D. Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
C. Daniel Myers President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Richard S. Eiswirth Jr. Chief Financial Officer, Chief Operating Officer
Age: 45
Bio & Compensation  - Reuters
Kenneth Green Ph.D. Senior Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation  - Reuters
David R. Holland Senior Vice President - Sales and Marketing
Age: 50
Bio & Compensation  - Reuters
Philip Ashman Senior Vice President, European Managing Director
Age: 49
Bio & Compensation  - Reuters
Susan Caballa Senior Vice President - Regulatory and Medical Affairs
Age: 69
Bio & Compensation  - Reuters
Brian K. Halak Ph.D. Independent Director
Age: 42
Bio & Compensation  - Reuters
James R. Largent Independent Director
Age: 64
Bio & Compensation  - Reuters
Calvin W. Roberts M.D. Independent Director
Age: 61
Bio & Compensation  - Reuters